content top

3 Cases of MH Following Intravitreal Injection with Ranibizumab

Poster Youngduk Kim Purpose: To report three cases of macular hole formation in patients who was administered intravitreal ranibizumab. Method: The first case was a 72-year-old man with age related macular degeneration and vitreomacular adhesion. The second case was a 76-year-old woman with subretinal haemorrhage and high PED. She was diagnosed with ARMD. The third case was 51-year-old woman with subretinal haemorrhage and high myopia....

Read More

Intravitreal Triamcinolone Versus Bevacizumab for Treatment of Subretinal Fluid in Diabetic Retinopathy

Poster V. Levent Karabas Purpose: To evaluate the efficacy of intravitreal triamcinolone acetonite (IVT) injection versus intravitreal bevacizumab (IVB) injection in the management of subretinal fluid in patients with diabetic retinopathy. Methods: Forty-seven patient affected by diabetic macular edema with subretinal fluid were included. Patients were assigned randomly to two groups. IVT group, patients who received 4mg/0.1ml...

Read More

Ocular Adverse Events Related to Intravitreal Ranibizumab in Patients with Exudative ARMD

Purpose: Anti-VEGF injections have been standard treatment of exudative age-related macular degeneration (ARMD) in recent years. However multiple and recurrent injections needed to maintain the efficacy of the treatment may lead to adverse side effects related to this regimen. The aim of this study was to find out ocular adverse events associated with intravitreal injection of ranibizumab for the treatment of exudative ARMD performed in a...

Read More

Effect of Intravitreal Ranibizumab on Cardiac Ischemic Parameters and Vascular Endothelial Function

Poster Altan Goktas Purpose: To evaluate the effect of intravitreal ranibizumab injection on cardiac ischemic parameters and vascular endothelial function. Methods: This observational, prospective case series included a total of 48 patients (23 patients with age-related macular degeneration and 25 patients with diabetic macular edema). All participants received intravitreal injections of 0.5 mg ranibizumab. Cardiac ischemic parameters...

Read More

Retinal Vessel Response to Intravitreal Bevacizumab in Diabetic Eyes

Poster 2 Osman Cekic To measure retinal vessel diameters following intravitreal bevacizumab injection in eyes with diabetic macular oedema.

Read More

Retinal Nerve Fiber Layer Thickness Change in Wet AMD Treated with Ranibizumab

Poster Ozen Ayranci Osmanbasoglu Advantages: To assess the effect of intravitreal (IV) ranibizumab therapy on retinal nerve fiber layer (RNFL) thickness. Methods: Fourteen eyes of 11 treatment naive patients with neovascular age related macular degeneration treated with ranibizumab were included. Patients were followed up by monthly examinations and IV ranibizumab injections were done as on needed basis. RNFL thickness s was measured by...

Read More
content top